Drugs / Almansour-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05171946 | Nov 2022 → Mar 2023 | vaccinia | Iman Almansour | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Almansour-001 | “IAU COVID-19 vaccine Almansour-001 consists of a plasmid DNA (pDNA) carrying a synthetic, codon-optimized, gene insert that encodes spike (S) gene of COVID-19.” NCT05171946 ↗1“Almansour-001” NCT05171946 ↗ |
| Modality | Vaccine | “thermally stable plasmid DNA (pDNA)-based vaccine candidate” NCT05171946 ↗ |
| Route | Intramuscular | “administered as intramuscular immunization (i.m.)” NCT05171946 ↗ |